Not a good buy right now for an impatient buyer: price is breaking below key support (S1 ~150) with bearish momentum signals.
Options positioning is defensively skewed (high put open interest vs calls), while today’s volume is thin—doesn’t confirm a durable upside turn.
Wall Street targets imply upside (PTs mostly ~205–220), but near-term tape is weak and hedge funds have been net sellers.
If you must act now (no waiting for a cleaner entry), this is a HOLD/AVOID new buys until the stock reclaims the pivot (156.95) or stabilizes closer to S2 (145.97) with improving momentum.
Trend/Momentum: Bearish near-term; MACD histogram is negative (-0.612) and expanding lower, signaling downside momentum is increasing.
RSI: RSI(6) ~38.35 (weak/near-oversold zone), which can allow for bounces, but it’s not a confirmed reversal signal by itself.
Moving averages: Converging MAs suggest indecision/transition, but current momentum favors bears.
Key levels (pre-market ~149.4):
Immediate support: S1 ~150.17 (currently slipping below), then S2 ~145.97.
Resistance/pivot: Pivot ~156.95; reclaiming this level would improve the bullish setup.
Upside resistances: R1 ~163.74, R2 ~167.93.
Pattern-based forward skew (similar candlesticks): Model implies a mild next-day drift (-0.34%) but positive bias over 1W (+6.76%) and 1M (+9.28%); this conflicts with current bearish momentum, so confirmation is needed.
Options Data
Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning: Put open interest (1838) materially exceeds call OI (674) → defensive/hedged sentiment in outstanding positioning.
Flow today: Put/call volume ratio 0.05 (calls dominating today), but total volume is very low (23 contracts), so the signal quality is limited.
Volatility: 30D IV ~58.35 vs HV ~53.11; IV percentile ~82.47 → options are priced rich, consistent with elevated event risk.
Event context: Earnings scheduled 2026-02-19 (After Hours) can keep IV elevated and drive sharp moves.
Technical Summary
Sell
10
Buy
3
Positive Catalysts
Earnings catalyst upcoming: QDEC 2025 earnings on 2026-02-19 (AH) could re-rate the stock if growth/margins surprise positively.
Strong revenue growth trend in latest reported quarter (2025/Q3 revenue +30.74% YoY) supports the long-term narrative.
Analyst stance broadly constructive: multiple firms at Overweight/Outperform/Buy with targets mostly >200 (material upside vs ~149–152 area).
Sector setup tailwinds cited by analysts (MedTech spending environment / product cycle commentary) may support sentiment in 2026.
Neutral/Negative Catalysts
with weakening MACD increases odds of a continuation toward S2 (~145.97).
Profitability: Net income -$5.212M (down -88.71% YoY) and EPS -$0.16 (down -89.19% YoY) → losses widened materially vs prior year.
Margins: Gross margin 71.09%, up +3.36% YoY → unit economics improved even as bottom-line weakened (likely opex/investment-driven).
Setup into next print: With QDEC 2025 earnings upcoming, the market will focus on whether revenue growth sustains while losses narrow.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Ratings leaned more constructive into early 2026 (Evercore upgraded to Outperform), while some firms trimmed targets modestly (Baird/Truist) but kept bullish stances; Goldman remains Neutral.
Notable updates:
2026-01-05 Evercore ISI: upgraded to Outperform; PT raised to $210 (from $194).
2026-01-09 Goldman Sachs: Neutral; PT raised to $211 (from $202).
2025-12-02 Morgan Stanley: Overweight; PT raised to $205 (from $195).
2025-12-16 Baird: Outperform; PT lowered to $220 (from $235).
2025-12-18 Truist: Buy; PT lowered to $215 (from $230).
Wall Street pros vs cons (as implied by the notes and PT actions):
Pros: expectation of normalized fundamentals, sector/MedTech setup, and meaningful upside to PTs.
Cons: targets being trimmed by some despite bullish ratings suggests valuation/performance mismatch concerns; Goldman staying Neutral indicates not everyone sees a clear near-term rerating.
Influential/political trading: No recent congress trading data available; insider trading trend is neutral (no significant activity recently).
People Also Watch
Wall Street analysts forecast IRTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRTC is 222 USD with a low forecast of 205 USD and a high forecast of 244 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast IRTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRTC is 222 USD with a low forecast of 205 USD and a high forecast of 244 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 146.750
Low
205
Averages
222
High
244
Current: 146.750
Low
205
Averages
222
High
244
Goldman Sachs
Neutral
maintain
$202 -> $211
AI Analysis
2026-01-09
Reason
Goldman Sachs
Price Target
$202 -> $211
AI Analysis
2026-01-09
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on iRhythm to $211 from $202 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
Evercore ISI
Vijay Kumar
In Line -> Outperform
upgrade
$194 -> $210
2026-01-05
Reason
Evercore ISI
Vijay Kumar
Price Target
$194 -> $210
2026-01-05
upgrade
In Line -> Outperform
Reason
Evercore ISI analyst Vijay Kumar upgraded iRhythm to Outperform from In Line with a price target of $210, up from $194.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IRTC
